ArticleJACC. Basic to translational science2026
Targeting the ERK Signaling Pathway to Halt Adventitia Remodeling of Ascending Thoracic Aortic Aneurysm.
Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Outer Layer Strikes Back: Putting the Adventitia Back on the Map in Thoracic Aortic Aneurysm.JACC. Basic to translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ascending thoracic aortic aneurysms (AsTAAs) are life-threatening and lack effective drug treatments. This study investigated whether abnormal mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) activation in adventitial pericytes contributes to aneurysm progression. Human AsTAA tissue showed vasa vasorum remodeling and displaced pericytes. Isolated AsTAA-pericytes showed increased MEK/ERK signaling, proliferation, migration, proteolytic activity, proinflammatory secretome, and altered angiogenic function. These changes were reversed by the MEK inhibitor PD0325901. In a mouse model, short-term MEKi treatment reduced aortic dilatation, improved compliance, preserved elastin, and lessened inflammation, without adverse effects. This is the first study identifying dysregulated adventitial pericytes as a hallmark of AsTAA, supporting MEKi as a promising therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.